FDG-PET might not contribute to improving survival in patients with locally advanced inoperable esophageal cancer

Jingu, Keiichi; Umezawa, Rei; Yamamoto, Takaya; Takeda, Kazuya; Ishikawa, Yojiro; Takahashi, Noriyoshi; Matsushita, Haruo

doi:10.1007/s10147-019-01428-8

Cited by 5 publications

(3 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Only patients with definitive evidence of unresectability (R2) should be excluded from esophagectomy (8). 18 F-fluorodeoxyglucose-Positron emission tomography (FDG-PET) has been covered in national health insurance for esophageal cancer. In surgically resectable ESCC, the value of standardized uptake value (SUV) max of FDG-PET is effective for responders of neoadjuvant therapy.…”

Section: Table 1 Representative Definitive Crt Regimen For Ct4 Escc In Japanmentioning

confidence: 99%

See 1 more Smart Citation

Surgical strategies for treatment of clinical T4 esophageal cancer in Japan

Yamada

Nohara

Enomoto

et al. 2021

GHM

View full text Add to dashboard Cite

Definitive chemoradiation (dCRT) is the mainstay treatment for cStage IVa esophageal squamous cell carcinoma (ESCC) with good performance status (PS), according to standard practice guidelines. Salvage surgery may incur operation complications and risk of mortality. According to the esophageal cancer practice guidelines outlined by the Japan Esophageal Society, when a tumor is residual and recurrent, chemotherapy and palliative symptomatic treatment is continued. However, salvage operation has been selected as a therapeutic option for recurrent or residual tumors after dCRT. There is weak evidence for not recommending surgery for cStage IVa ESCC exhibiting residual disease following dCRT. It has been reported that during salvage surgery the only prognostic factor that is thought to be performed is complete resection (R0), but at the same time, salvage esophagectomy increases the incidence of postoperative complications and mortality. The phase II chemoselection study by Yokota T et al. in Japan showed that multidisciplinary treatment initiated by induction therapy, in which docetaxel is added to cisplatin and 5-fluorouracil, resulted in a good prognosis in the short term. In this review, we discuss the surgical strategy and future of unresectable clinical T4 (cT4) ESCC.

show abstract

Section: Table 1 Representative Definitive Crt Regimen For Ct4 Escc In Japanmentioning

confidence: 99%

“…Recently, PET has proven to be an important modality for evaluation of treatment for T4 ESCC (17). Conversely, Jingu et al reported that FDG -PET may not contribute to improving survival for locally advanced unresectable ESCC (18).…”

Section: Table 1 Representative Definitive Crt Regimen For Ct4 Escc In Japanmentioning

confidence: 99%

Surgical strategies for treatment of clinical T4 esophageal cancer in Japan

Yamada

Nohara

Enomoto

et al. 2021

GHM

View full text Add to dashboard Cite

show abstract

“…Esophageal cancer (ESCA) is one of the most common cancers worldwide, including China, with the ninth-highest incidence and sixth-highest mortality worldwide ( Chen et al, 2016 ; Bray et al, 2018 ). At present, due to the lack of target molecules for early diagnosis, drug treatment, and evaluation of prognosis of ESCA, the five-year survival rate of cancer patients remains low ( Zarean et al, 2018 ; Jingu et al, 2019 ; Lin et al, 2019 ). Therefore, new biomarkers are sought after to improve the diagnosis rate and to find new targeted therapies to improve the overall survival (OS) of ESCA patients.…”

Section: Introductionmentioning

confidence: 99%

SPDL1 Overexpression Is Associated With the 18F-FDG PET/CT Metabolic Parameters, Prognosis, and Progression of Esophageal Cancer

et al. 2022

View full text Add to dashboard Cite

Esophageal cancer (ESCA) is one of the common malignant tumors. The roles and signaling mechanisms of spindle apparatus coiled-coil protein 1 (SPDL1) in ESCA progression have not been reported previously. Therefore, the expression levels and potential clinical roles of SPDL1 were investigated using data from multiple databases and tissue samples of 53 ESCA patients who underwent 18F-FDG positron emission tomography (PET)/computed tomography (CT) before therapy. The signaling mechanisms of SPDL1 involved in ESCA progression were investigated via bioinformatics analysis. The effects of SPDL1 on the growth and migration of ESCA cells were investigated using CCK-8, Edu, and transwell assays. SPDL1 was upregulated in ESCA tissues. Increased SPDL1 expression was associated with age, grade, drinking history, cancer stage, lymph node metastasis, TP53 mutation, and poor prognosis in patients with ESCA. SPDL1 overexpression was significantly correlated with SUVmax, SUVmean, and TLG of PET/CT. SPDL1 silencing inhibited cell proliferation, migration, and invasion. SPDL1 was significantly enriched in cell cycle, spliceosome, DNA replication, and other processes. The hub genes of a constructed protein–protein interaction network included CDK1, BUB1, CCNB1, BUB1B, CCNA2, CDC20, MAD2L1, AURKB, NDC80, and PLK1, which were related to SPDL1 expression. The findings of this study suggest that SPDL1 may serve as a biomarker of ESCA prognosis.

show abstract